HQK 1001

Drug Profile

HQK 1001

Alternative Names: HQK-1001; ST-20

Latest Information Update: 29 Jul 2015

Price : $50

At a glance

  • Originator HemaQuest Pharmaceuticals
  • Class Antianaemics; Small molecules; Volatile fatty acids
  • Mechanism of Action Erythropoiesis stimulants; Fetal haemoglobin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia; Beta-thalassaemia
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Beta-thalassaemia; Sickle cell anaemia

Most Recent Events

  • 10 Jun 2013 HemaQuest completes enrolment in its phase IIb trial for Sickle cell anaemia (twice-daily dosing) in USA, Canada, Jamaica, Egypt & Lebanon (NCT01601340)
  • 31 Jan 2013 Boston University & HemaQuest complete a phase II trial in Beta-thalassaemia in Lebanon (NCT01642758)
  • 31 Jul 2012 Phase-II clinical trials in Sickle cell anaemia in Lebanon (PO, twice-daily dosing)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top